Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma Journal Article

  


Authors: Goodman, K. A.; Riedel, E.; Serrano, V.; Gulati, S.; Moskowitz, C. H.; Yahalom, J.
Article Title: Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma
Abstract: Purpose: To evaluate the risk of late morbidity and mortality, and to assess long-term health-related quality of life (QOL) among patients with relapsed/refractory Hodgkin's lymphoma (HL) after high-dose chemoradiotherapy (HDT) and autologous stem-cell rescue (ASCR). Patients and Methods: From 1985 to 1998, 218 patients with HL were treated on HDT with ASCR salvage protocols. Of these 218, 153 (70%) who survived ≥ 2 years after ASCR were evaluated for late morbidity and mortality from causes other than HL. QOL information was obtained through self-administered questionnaires. Risk ratios (RR) were calculated to compare observed second malignancy (SM) rates in this cohort with expected SM rates from the Surveillance Epidemiology and End Results (SEER) registry. Results: Median follow-up after ASCR was 11.5 years. Among 153 patients, there were 53 deaths; 33 from HL and 20 from other causes. Thirteen deaths were caused by SM, with median time from ASCR to SM diagnosis of 9 years (range, 3 to 18 years). The RR of SM was 6.5 (95% CI, 3.6 to 10.7) when compared with the general population, but 2.4 (95% CI, 1.4 to 4.05) when compared with patients with HL. Global QOL of ASCR survivors was comparable with the general population, but for specific domains, respondents' scores indicated reduced functioning and worse symptoms. Conclusion: HL accounts for most deaths among patients surviving HDT and ASCR. Survivors of ASCR had an elevated risk of SM compared with the cancer risk in the general population, but when compared with patients with HL in SEER, the risk was less pronounced. © 2008 by American Society of Clinical Oncology.
Keywords: adolescent; adult; cancer chemotherapy; cancer survival; child; child, preschool; middle aged; treatment failure; major clinical study; prednisone; salvage therapy; doxorubicin; cancer risk; cancer radiotherapy; chemotherapy, adjuvant; radiotherapy, adjuvant; methotrexate; drug megadose; follow-up studies; carboplatin; dacarbazine; quality of life; etoposide; antineoplastic combined chemotherapy protocols; recurrence; cyclophosphamide; vincristine; stem cell transplantation; drug resistance, neoplasm; carmustine; chlormethine; ifosfamide; procarbazine; hodgkin disease; time factors; risk assessment; questionnaires; kaplan-meiers estimate; vincristine sulfate; mitoxantrone; bleomycin; new york city; seer program; cancer relapse; second cancer; vinblastine sulfate; transplantation, autologous; mitoguazone
Journal Title: Journal of Clinical Oncology
Volume: 26
Issue: 32
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2008-11-10
Start Page: 5240
End Page: 5247
Language: English
DOI: 10.1200/jco.2007.15.5507
PUBMED: 18809615
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-56049120865&partnerID=40&md5=35e4fd90e4e80681c6b44616cc73a217
Notes: --- - "Cited By (since 1996): 11" - "Export Date: 17 November 2011" - "CODEN: JCOND" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Joachim Yahalom
    625 Yahalom
  2. Elyn Renee Stubblefield
    203 Stubblefield
  3. Craig Moskowitz
    407 Moskowitz
  4. Karyn A Goodman
    257 Goodman
  5. Victoria Serrano
    9 Serrano
Related MSK Work